A Phase 2 Study of IC14 in Acute Respiratory Distress Syndrome
Status:
Withdrawn
Trial end date:
2020-06-01
Target enrollment:
Participant gender:
Summary
Acute Respiratory Distress Syndrome (ARDS) patients will be randomized to receive either IC14
(a single dose of 4 mg/kg followed by 2 mg/kg on Days 2-4) or placebo. Study participation
will be for a total of 28 days.